{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T10:05:34Z","timestamp":1791021934132,"version":"4.1.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,7,25]],"date-time":"2022-07-25T00:00:00Z","timestamp":1658707200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,25]],"date-time":"2022-07-25T00:00:00Z","timestamp":1658707200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Cancer associated fibroblasts (CAFs) support tumors via multiple mechanisms, including maintaining the immunosuppressive tumor microenvironment and limiting infiltration of immune cells. The prolyl isomerase Pin1, whose overexpression in CAFs has not been fully profiled yet, plays critical roles in tumor initiation and progression. To decipher effects of selective Pin1 inhibition in CAFs on pancreatic cancer, here we formulate a DNA-barcoded micellular system (DMS) encapsulating the Pin1 inhibitor AG17724. DMS functionalized with CAF-targeting anti-FAP-\u03b1 antibodies (antiCAFs-DMS) can selectively inhibit Pin1 in CAFs, leading to efficacious but transient tumor growth inhibition. We further integrate DNA aptamers (AptT), which can engage CD8+ T lymphocytes, to obtain a bispecific antiCAFs-DMS-AptT system. AntiCAFs-DMS-AptT inhibits tumor growth in subcutaneous and orthotopic pancreatic cancer models.<\/jats:p>","DOI":"10.1038\/s41467-022-31928-7","type":"journal-article","created":{"date-parts":[[2022,7,25]],"date-time":"2022-07-25T13:03:40Z","timestamp":1658754220000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["Pancreatic tumor eradication via selective Pin1 inhibition in cancer-associated fibroblasts and T lymphocytes engagement"],"prefix":"10.1038","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4434-3120","authenticated-orcid":false,"given":"Jiaye","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7911-9551","authenticated-orcid":false,"given":"Yang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunyang","family":"Mu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kewei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenshuang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingyao","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junyi","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1339-0760","authenticated-orcid":false,"given":"Yang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dujiang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaixiang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingyang","family":"Ning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoying","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinyun","family":"Ni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zongguang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3973-2140","authenticated-orcid":false,"given":"Yiguo","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2850-7308","authenticated-orcid":false,"given":"Xiaofeng","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1871-272X","authenticated-orcid":false,"given":"Tianfu","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1461-3954","authenticated-orcid":false,"given":"Zhihui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2558-7015","authenticated-orcid":false,"given":"Yong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,25]]},"reference":[{"key":"31928_CR1","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1038\/nmat4822","volume":"16","author":"R Kuai","year":"2016","unstructured":"Kuai, R., Ochyl, L. J., Bahjat, K. S., Schwendeman, A. & Moon, J. J. Designer vaccine nanodiscs for personalized cancer immunotherapy. Nat. Mater. 16, 489\u2013496 (2016).","journal-title":"Nat. Mater."},{"key":"31928_CR2","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1007\/s40262-016-0405-4","volume":"55","author":"M Zhu","year":"2016","unstructured":"Zhu, M. et al. Blinatumomab, a bispecific T-cell Engager (BiTE\u00ae) for CD-19 targeted cancer immunotherapy: clinical pharmacology and its implications. Clin. Pharmacokinet. 55, 1271\u20131288 (2016).","journal-title":"Clin. Pharmacokinet."},{"key":"31928_CR3","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1126\/science.342.6165.1432","volume":"342","author":"J Couzin-Frankel","year":"2013","unstructured":"Couzin-Frankel, J. Cancer immunotherapy. Science 342, 1432\u20131433 (2013).","journal-title":"Science"},{"key":"31928_CR4","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1038\/nrc.2016.97","volume":"16","author":"AD Fesnak","year":"2016","unstructured":"Fesnak, A. D., June, C. H. & Levine, B. L. Engineered T cells: the promise and challenges of cancer immunotherapy. Nat. Rev. Cancer 16, 566\u2013581 (2016).","journal-title":"Nat. Rev. Cancer"},{"key":"31928_CR5","doi-asserted-by":"publisher","first-page":"2598","DOI":"10.1158\/1535-7163.MCT-17-0386","volume":"16","author":"AM Goodman","year":"2017","unstructured":"Goodman, A. M. et al. Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers. Mol. Cancer Ther. 16, 2598\u20132608 (2017).","journal-title":"Mol. Cancer Ther."},{"key":"31928_CR6","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/j.cell.2017.01.018","volume":"168","author":"N McGranahan","year":"2017","unstructured":"McGranahan, N. & Swanton, C. Clonal heterogeneity and tumor evolution: past, present, and the future. Cell 168, 613\u2013628 (2017).","journal-title":"Cell"},{"key":"31928_CR7","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1038\/s41591-021-01233-9","volume":"27","author":"I Vitale","year":"2021","unstructured":"Vitale, I., Shema, E., Loi, S. & Galluzzi, L. Intratumoral heterogeneity in cancer progression and response to immunotherapy. Nat. Med. 27, 212\u2013224 (2021).","journal-title":"Nat. Med."},{"key":"31928_CR8","doi-asserted-by":"crossref","unstructured":"Huang, K. W. et al. Highly efficient and tumor-selective nanoparticles for dual-targeted immunogene therapy against cancer. Sci. Adv. 6, eaax5032 (2020).","DOI":"10.1126\/sciadv.aax5032"},{"key":"31928_CR9","doi-asserted-by":"crossref","unstructured":"Ferrarelli, L. K. CAFs complicate immunotherapy. Sci. Signal. 10, (2017).","DOI":"10.1126\/scisignal.aar5583"},{"key":"31928_CR10","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1126\/science.aaa6204","volume":"348","author":"JA Joyce","year":"2015","unstructured":"Joyce, J. A. & Fearon, D. T. T cell exclusion, immune privilege, and the tumor microenvironment. Science 348, 74\u201380 (2015).","journal-title":"Science"},{"key":"31928_CR11","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/s41573-018-0004-1","volume":"18","author":"X Chen","year":"2018","unstructured":"Chen, X. & Song, E. Turning foes to friends: targeting cancer-associated fibroblasts. Nat. Rev. Drug Discov. 18, 99\u2013115 (2018).","journal-title":"Nat. Rev. Drug Discov."},{"key":"31928_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-018-06654-8","volume":"9","author":"A Chakravarthy","year":"2018","unstructured":"Chakravarthy, A., Khan, L., Bensler, N. P., Bose, P. & De Carvalho, D. D. TGF-\u03b2-associated extracellular matrix genes link cancer-associated fibroblasts to immune evasion and immunotherapy failure. Nat. Commun. 9, 1\u201310 (2018).","journal-title":"Nat. Commun."},{"key":"31928_CR13","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/s41577-019-0269-6","volume":"20","author":"DJ Irvine","year":"2020","unstructured":"Irvine, D. J. & Dane, E. L. Enhancing cancer immunotherapy with nanomedicine. Nat. Rev. Immunol. 20, 321\u2013334 (2020).","journal-title":"Nat. Rev. Immunol."},{"key":"31928_CR14","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1038\/s41571-018-0007-1","volume":"15","author":"KC Valkenburg","year":"2018","unstructured":"Valkenburg, K. C., De Groot, A. E. & Pienta, K. J. Targeting the tumour stroma to improve cancer therapy. Nat. Rev. Clin. Oncol. 15, 366\u2013381 (2018).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"31928_CR15","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.semcancer.2019.08.002","volume":"59","author":"M Marzagalli","year":"2019","unstructured":"Marzagalli, M., Ebelt, N. D. & Manuel, E. R. Unraveling the crosstalk between melanoma and immune cells in the tumor microenvironment. Semin. Cancer Biol. 59, 236\u2013250 (2019).","journal-title":"Semin. Cancer Biol."},{"key":"31928_CR16","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1016\/j.ccell.2017.10.005","volume":"32","author":"V Kumar","year":"2017","unstructured":"Kumar, V. et al. Cancer-associated fibroblasts neutralize the anti-tumor effect of CSF1 receptor blockade by inducing PMN-MDSC infiltration of tumors. Cancer Cell 32, 654\u2013668.e5 (2017).","journal-title":"Cancer Cell"},{"key":"31928_CR17","doi-asserted-by":"publisher","first-page":"4753","DOI":"10.1016\/j.cell.2021.07.020","volume":"184","author":"K Koikawa","year":"2021","unstructured":"Koikawa, K. et al. Targeting Pin1 renders pancreatic cancer eradicable by synergizing with immunochemotherapy. Cell 184, 4753\u20134771.e27 (2021).","journal-title":"Cell"},{"key":"31928_CR18","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/nrc.2016.49","volume":"16","author":"XZ Zhou","year":"2016","unstructured":"Zhou, X. Z. & Lu, K. P. The isomerase PIN1 controls numerous cancer-driving pathways and is a unique drug target. Nat. Rev. Cancer 16, 463\u2013478 (2016).","journal-title":"Nat. Rev. Cancer"},{"key":"31928_CR19","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/nrc2107","volume":"7","author":"ES Yeh","year":"2007","unstructured":"Yeh, E. S. & Means, A. R. PIN1, the cell cycle and cancer. Nat. Rev. Cancer 7, 381\u2013388 (2007).","journal-title":"Nat. Rev. Cancer"},{"key":"31928_CR20","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1093\/nar\/29.3.767","volume":"29","author":"SH Chao","year":"2001","unstructured":"Chao, S. H., Greenleaf, A. L. & Price, D. H. Juglone, an inhibitor of the peptidyl-prolyl isomerase Pin1, also directly blocks transcription. Nucleic Acids Res. 29, 767\u2013773 (2001).","journal-title":"Nucleic Acids Res."},{"key":"31928_CR21","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1038\/s41589-021-00786-7","volume":"17","author":"C Dubiella","year":"2021","unstructured":"Dubiella, C. et al. Sulfopin is a covalent inhibitor of Pin1 that blocks Myc-driven tumors in vivo. Nat. Chem. Biol. 17, 954\u2013963 (2021).","journal-title":"Nat. Chem. Biol."},{"key":"31928_CR22","doi-asserted-by":"publisher","unstructured":"Hleihel, R. et al. A Pin1\/PML\/P53 axis activated by retinoic acid in NPM-1c-acute myeloid leukemia. Haematologica https:\/\/doi.org\/10.3324\/HAEMATOL.2020.274878 (2020).","DOI":"10.3324\/HAEMATOL.2020.274878"},{"key":"31928_CR23","first-page":"457","volume":"21","author":"S Wei","year":"2015","unstructured":"Wei, S. et al. Active Pin1 is a key target of all-trans retinoic acid in acute promyelocytic leukemia and breast cancer. Nat. Med. 2015 215 21, 457\u2013466 (2015).","journal-title":"Nat. Med. 2015 215"},{"key":"31928_CR24","first-page":"1","volume":"8","author":"E Campaner","year":"2017","unstructured":"Campaner, E. et al. A covalent PIN1 inhibitor selectively targets cancer cells by a dual mechanism of action. Nat. Commun. 2017 81 8, 1\u201315 (2017).","journal-title":"Nat. Commun. 2017 81"},{"key":"31928_CR25","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.addr.2021.02.012","volume":"172","author":"H Liu","year":"2021","unstructured":"Liu, H., Shi, Y. & Qian, F. Opportunities and delusions regarding drug delivery targeting pancreatic cancer-associated fibroblasts. Adv. Drug Deliv. Rev. 172, 37\u201351 (2021).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"31928_CR26","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.biomaterials.2017.08.002","volume":"144","author":"L Wang","year":"2017","unstructured":"Wang, L. et al. Terminating the criminal collaboration in pancreatic cancer: Nanoparticle-based synergistic therapy for overcoming fibroblast-induced drug resistance. Biomaterials 144, 105\u2013118 (2017).","journal-title":"Biomaterials"},{"key":"31928_CR27","doi-asserted-by":"publisher","first-page":"12357","DOI":"10.1021\/acsnano.9b04857","volume":"13","author":"J Lang","year":"2019","unstructured":"Lang, J. et al. Reshaping prostate tumor microenvironment to suppress metastasis via cancer-associated fibroblast inactivation with peptide-assembly-based nanosystem. ACS Nano 13, 12357\u201312371 (2019).","journal-title":"ACS Nano"},{"key":"31928_CR28","doi-asserted-by":"publisher","first-page":"8520","DOI":"10.1021\/acsnano.8b04066","volume":"12","author":"J Li","year":"2018","unstructured":"Li, J. et al. Cell membrane coated semiconducting polymer nanoparticles for enhanced multimodal cancer phototheranostics. ACS Nano 12, 8520\u20138530 (2018).","journal-title":"ACS Nano"},{"key":"31928_CR29","doi-asserted-by":"publisher","first-page":"1900631","DOI":"10.1002\/smll.201900631","volume":"15","author":"Y Pei","year":"2019","unstructured":"Pei, Y. et al. Sequential targeting TGF-\u03b2 signaling and KRAS mutation increases therapeutic efficacy in pancreatic cancer. Small 15, 1900631 (2019).","journal-title":"Small"},{"key":"31928_CR30","doi-asserted-by":"publisher","unstructured":"Yaari, Z. et al. Theranostic barcoded nanoparticles for personalized cancer medicine. Nat. Commun. https:\/\/doi.org\/10.1038\/ncomms13325 (2016).","DOI":"10.1038\/ncomms13325"},{"key":"31928_CR31","doi-asserted-by":"publisher","unstructured":"Dahlman, J. E. et al. Barcoded nanoparticles for high throughput in vivo discovery of targeted therapeutics. Proc. Natl. Acad. Sci. USA https:\/\/doi.org\/10.1073\/pnas.1620874114 (2017).","DOI":"10.1073\/pnas.1620874114"},{"key":"31928_CR32","doi-asserted-by":"publisher","unstructured":"Huang, X. et al. DNA scaffolds enable efficient and tunable functionalization of biomaterials for immune cell modulation. Nat. Nanotechnol. https:\/\/doi.org\/10.1038\/s41565-020-00813-z (2021).","DOI":"10.1038\/s41565-020-00813-z"},{"key":"31928_CR33","doi-asserted-by":"publisher","unstructured":"Xia, L. Y., Tang, Y. N., Zhang, J., Dong, T. Y. & Zhou, R. X. Advances in the DNA nanotechnology for the cancer biomarkers analysis: attributes and applications. Semin. Cancer Biol. https:\/\/doi.org\/10.1016\/j.semcancer.2021.12.012 (2022).","DOI":"10.1016\/j.semcancer.2021.12.012"},{"key":"31928_CR34","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1038\/nrd1033","volume":"2","author":"J Milton Harris","year":"2003","unstructured":"Milton Harris, J. & Chess, R. B. Effect of pegylation on pharmaceuticals. Nat. Rev. Drug Discov. 2, 214\u2013221 (2003).","journal-title":"Nat. Rev. Drug Discov."},{"key":"31928_CR35","doi-asserted-by":"publisher","first-page":"5657","DOI":"10.1073\/pnas.91.12.5657","volume":"91","author":"MJ Scanlan","year":"1994","unstructured":"Scanlan, M. J. et al. Molecular cloning of fibroblast activation protein alpha, a member of the serine protease family selectively expressed in stromal fibroblasts of epithelial cancers. Proc. Natl. Acad. Sci. 91, 5657\u20135661 (1994).","journal-title":"Proc. Natl. Acad. Sci."},{"key":"31928_CR36","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1038\/s41551-019-0411-6","volume":"3","author":"N Kacherovsky","year":"2019","unstructured":"Kacherovsky, N. et al. Traceless aptamer-mediated isolation of CD8+ T cells for chimeric antigen receptor T-cell therapy. Nat. Biomed. Eng. 3, 783\u2013795 (2019).","journal-title":"Nat. Biomed. Eng."},{"key":"31928_CR37","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1016\/j.jconrel.2020.02.040","volume":"321","author":"Q Yu","year":"2020","unstructured":"Yu, Q. et al. Targeting cancer-associated fibroblasts by dual-responsive lipid-albumin nanoparticles to enhance drug perfusion for pancreatic tumor therapy. J. Control. Release 321, 564\u2013575 (2020).","journal-title":"J. Control. Release"},{"key":"31928_CR38","doi-asserted-by":"publisher","first-page":"5613","DOI":"10.1016\/j.bmcl.2009.08.034","volume":"19","author":"C Guo","year":"2009","unstructured":"Guo, C. et al. Structure-based design of novel human Pin1 inhibitors (I). Bioorg. Med. Chem. Lett. 19, 5613\u20135616 (2009).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"31928_CR39","doi-asserted-by":"publisher","first-page":"2210","DOI":"10.1016\/j.bmcl.2010.02.033","volume":"20","author":"L Dong","year":"2010","unstructured":"Dong, L. et al. Structure-based design of novel human Pin1 inhibitors (II). Bioorg. Med. Chem. Lett. 20, 2210\u20132214 (2010).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"31928_CR40","doi-asserted-by":"publisher","first-page":"4187","DOI":"10.1016\/j.bmcl.2014.07.044","volume":"24","author":"C Guo","year":"2014","unstructured":"Guo, C. et al. Structure-based design of novel human Pin1 inhibitors (III): optimizing affinity beyond the phosphate recognition pocket. Bioorg. Med. Chem. Lett. 24, 4187\u20134191 (2014).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"31928_CR41","doi-asserted-by":"publisher","unstructured":"Lu, Z. & Hunter, T. Prolyl isomerase Pin1 in cancer. Cell Res. https:\/\/doi.org\/10.1038\/cr.2014.109 (2014).","DOI":"10.1038\/cr.2014.109"},{"key":"31928_CR42","doi-asserted-by":"publisher","unstructured":"Lu, K. P. & Zhou, X. Z. The prolyl isomerase PIN1: A pivotal new twist in phosphorylation signalling and disease. Nat. Rev. Mol. Cell Biol. https:\/\/doi.org\/10.1038\/nrm2261 (2007).","DOI":"10.1038\/nrm2261"},{"key":"31928_CR43","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1136\/gutjnl-2011-301220","volume":"61","author":"M Erkan","year":"2012","unstructured":"Erkan, M. et al. StellaTUM: current consensus and discussion on pancreatic stellate cell research. Gut 61, 172\u2013178 (2012).","journal-title":"Gut"},{"key":"31928_CR44","doi-asserted-by":"publisher","first-page":"2056","DOI":"10.1053\/j.gastro.2018.12.038","volume":"156","author":"VP Balachandran","year":"2019","unstructured":"Balachandran, V. P., Beatty, G. L. & Dougan, S. K. Broadening the impact of immunotherapy to pancreatic cancer: challenges and opportunities. Gastroenterology 156, 2056\u20132072 (2019).","journal-title":"Gastroenterology"},{"key":"31928_CR45","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1038\/s41571-020-0363-5","volume":"17","author":"WJ Ho","year":"2020","unstructured":"Ho, W. J., Jaffee, E. M. & Zheng, L. The tumour microenvironment in pancreatic cancer \u2014 clinical challenges and opportunities. Nat. Rev. Clin. Oncol. 17, 527\u2013540 (2020).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"31928_CR46","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.ccell.2017.02.008","volume":"31","author":"KG Anderson","year":"2017","unstructured":"Anderson, K. G., Stromnes, I. M. & Greenberg, P. D. Obstacles posed by the tumor microenvironment to t cell activity: a case for synergistic therapies. Cancer Cell 31, 311\u2013325 (2017).","journal-title":"Cancer Cell"},{"key":"31928_CR47","doi-asserted-by":"crossref","unstructured":"Nicolas-Boluda, A. et al. Tumor stiffening reversion through collagen crosslinking inhibition improves t cell migration and anti-pd-1 treatment. Elife 10, e58688 (2021).","DOI":"10.7554\/eLife.58688"},{"key":"31928_CR48","doi-asserted-by":"publisher","first-page":"9562","DOI":"10.1021\/acsnano.9b09884","volume":"14","author":"Y Yang","year":"2020","unstructured":"Yang, Y. et al. Circular bispecific aptamer-mediated artificial intercellular recognition for targeted T cell immunotherapy. ACS Nano 14, 9562\u20139571 (2020).","journal-title":"ACS Nano"},{"key":"31928_CR49","doi-asserted-by":"publisher","first-page":"4941","DOI":"10.1158\/0008-5472.CAN-09-0547","volume":"69","author":"PA Baeuerle","year":"2009","unstructured":"Baeuerle, P. A. & Reinhardt, C. Bispecific T-cell engaging antibodies for cancer therapy. Cancer Res. 69, 4941\u20134944 (2009).","journal-title":"Cancer Res."},{"key":"31928_CR50","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1038\/nnano.2017.69","volume":"12","author":"H Yuan","year":"2017","unstructured":"Yuan, H. et al. Multivalent bi-specific nanobioconjugate engager for targeted cancer immunotherapy. Nat. Nanotechnol. 12, 763\u2013769 (2017).","journal-title":"Nat. Nanotechnol."},{"key":"31928_CR51","first-page":"851","volume":"22","author":"H Jiang","year":"2016","unstructured":"Jiang, H. et al. Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy. Nat. Med. 2016 228 22, 851\u2013860 (2016).","journal-title":"Nat. Med. 2016 228"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-31928-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-31928-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-31928-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T13:31:57Z","timestamp":1669296717000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-31928-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,25]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["31928"],"URL":"https:\/\/doi.org\/10.1038\/s41467-022-31928-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2022.01.31.478589","asserted-by":"object"}]},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,25]]},"assertion":[{"value":"7 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4308"}}